Herpesvirus Antiviral Drug Screen

Summary Herpesviruses continue to be a significant medical problem, causing painful chronic genital infections as well as devastating neonatal infections. To address these problems, Harvard Medical School faculty member Dr. David Knipe has looked at factors that control the replication of HSV. ICP-4 is the herpes protein most involved in HSV transcriptional regulation, and the activity of ICP-4 itself is modified by phosphorylation. As a result, compounds that affect the phosphorylation of ICP-4 should show potential as HSV antivirals.

Dr. Knipe has developed a method that allows researchers to rapidly screen for compounds that affect the phosphorylation of ICP-4, and thus should show potential as HSV antivirals in subsequent screens. US Patent issued 2/9/99 5,869,234

Applications Herpesvirus antiviral drug discovery tool. Drug Screening Method. ADVANTAGES:
" Allows researchers to rapidly screen compounds in vitro for potential antiviral activity
" Can be configured for HTS

Inventor(s): Knipe, David M.

Type of Offer: Licensing



« More Pharmaceutical Patents

---